|
Synonyms
|
Cytokine Zcyto21
|
|
Species
|
Human
|
|
Accession
|
Q8IU54
|
|
GeneID
|
282618
|
|
Source
|
Escherichia coli.
|
|
Molecular Weight
|
重组人干扰素-λ1/白细胞介素-29蛋白Approximately 19.8 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids.
|
|
Quantity
|
5µg/20µg/1000µg
|
|
AA Sequence
|
GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T
|
|
Purity
|
> 97 % by SDS-PAGE and HPLC analyses.
|
|
Biological Activity
|
重组人干扰素-λ1/白细胞介素-29蛋白Fully biologically active when compared to standard. The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml, corresponding to a specific activity of > 2.0 × 105 IU/mg.
|
|
Physical Appearance
|
Sterile Filtered White lyophilized (freeze-dried) powder.
|
|
Formulation
|
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
|
|
Endotoxin
|
Less than 1 EU/μg of rHuIFN-λ1/IL-29 as determined by LAL method.
|
|
Reconstitution
|
重组人干扰素-λ1/白细胞介素-29蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
|
|
Storage
|
This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
|
|
重组人干扰素-λ1/白细胞介素-29蛋白
|
|
|
Reference
|
1. Miller EK, Hernandez JZ, Wimmenauer V, et al. 2012. Am J Respir Crit Care Med, 185: 508-16.
2. Li Y, Xie J, Xu X, et al. 2012. Protein Cell,
3. Jordan WJ, Eskdale J, Srinivas S, et al. 2007. Genes Immun, 8: 254-61.
4. Pekarek V, Srinivas S, Eskdale J, et al. 2007. Genes Immun, 8: 177-80.
5. Megjugorac NJ, Gallagher GE, Gallagher G. 2010. Blood, 115: 4185-90.
|
|
Background
|
IL-28A, IL-28B, and IL-29, also named interferon-λ2 (IFN-λ2), IFN-λ3, and IFN-λ1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13 % a.a. sequence identity) and the type I IFN family (15-19 % a.a. sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor β (IL-10 Rβ) and a novel IL-28 receptor α (IL-28 Rα, also known as IFN-λR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.
|
